[go: up one dir, main page]

AR034173A1 - Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos - Google Patents

Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos

Info

Publication number
AR034173A1
AR034173A1 ARP010104957A ARP010104957A AR034173A1 AR 034173 A1 AR034173 A1 AR 034173A1 AR P010104957 A ARP010104957 A AR P010104957A AR P010104957 A ARP010104957 A AR P010104957A AR 034173 A1 AR034173 A1 AR 034173A1
Authority
AR
Argentina
Prior art keywords
group
carbonyl
hydrogen
branched
alkyl
Prior art date
Application number
ARP010104957A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR034173A1 publication Critical patent/AR034173A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Un compuesto de piperazina sustituida que tiene la fórmula (1), en la cual: m = 1, 2 ó 3; q = NH, O ó S; cada uno de R1, R2, R3, R4 y R5 es independientemente seleccionado entre el grupo que consiste en hidrógeno, OR20 y alquilo C1-5 lineal o ramificado; cada uno de R6, R7 y R8 es independientemente hidrógeno; cada uno de R9, R10, R11, R12, R13, R14, R15 y R16 es independientemente seleccionado entre el grupo que consiste en hidrógeno y alquilo C1-4 lineal o ramificado, o donde R9 y R10 juntos pueden formar un carbonilo o R11 y R12 juntos pueden formar un carbonilo o R13 y R14 juntos pueden formar un carbonilo o R15 y R16 juntos pueden formar un carbonilo; R17 es seleccionado del grupo que consiste en benzoxazolilo, benzotiazolilo, quinoxalinilo, piridinilo, quinolinilo, isoquinolinilo e indolilo, en donde cada grupos está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste de CON(R20)2, alquilo C1-15 lineal o ramificado y arilo, en donde los sustituyentes arilo están opcionalmente sustituidos con 1 sustituyentes seleccionado del grupo consistente en CF3; y R20 es hidrógeno; donde los compuestos son útiles en terapia para la protección de los músculos esqueléticos contra el deterioro producido como resultado de trauma, la protección de los músculos esqueléticos con posterioridad a enfermedades musculares o sistémicas tales como claudicación intermitente, para el tratamiento de estados de shock, para la conservación de tejidos y órganos de donantes empleados en transplantes, el tratamiento de enfermedades cardiovasculares entre las que se incluyen las arritmias auriculares y ventriculares, la angina de Prinzmetal (variante), la angina estable y angina inducida por el ejercicio, la enfermedad cardíaca congestiva y el infarto de miocardio. También se describen composiciones farmacéuticas que las comprenden y el uso de las mismas para la elaboración de medicamentos.
ARP010104957A 2000-10-23 2001-10-23 Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos AR034173A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/694,155 US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives

Publications (1)

Publication Number Publication Date
AR034173A1 true AR034173A1 (es) 2004-02-04

Family

ID=24787627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104957A AR034173A1 (es) 2000-10-23 2001-10-23 Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos

Country Status (23)

Country Link
US (4) US6573264B1 (es)
EP (1) EP1339701B1 (es)
JP (1) JP4138489B2 (es)
KR (1) KR20030044029A (es)
CN (1) CN1303074C (es)
AR (1) AR034173A1 (es)
AT (1) ATE353882T1 (es)
AU (1) AU2002255466B2 (es)
CA (1) CA2426535A1 (es)
DE (1) DE60126643T2 (es)
ES (1) ES2279790T3 (es)
HU (1) HUP0303552A3 (es)
IL (2) IL155294A0 (es)
MX (1) MXPA03003531A (es)
NO (2) NO20031784L (es)
NZ (1) NZ525259A (es)
PL (1) PL362004A1 (es)
PT (1) PT1339701E (es)
RU (1) RU2243970C1 (es)
SI (1) SI1339701T1 (es)
TW (1) TWI286135B (es)
WO (1) WO2002064576A1 (es)
ZA (1) ZA200302990B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
DK1406898T3 (da) * 2001-07-19 2005-05-30 Cv Therapeutics Inc Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US7056924B2 (en) * 2002-07-18 2006-06-06 Cv Therapeutics, Inc. Substituted heterocyclic compounds
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP2006510670A (ja) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
NZ541069A (en) * 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
ES2387909T3 (es) * 2003-01-14 2012-10-03 Cytokinetics, Inc. Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
NZ541306A (en) * 2003-01-17 2008-07-31 Cv Therapeutics Inc Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases
NZ544449A (en) * 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US7163944B2 (en) * 2004-01-26 2007-01-16 Kowa Co., Ltd. Cyclic diamine compound and pharmaceutical containing the same
PL216049B1 (pl) 2004-06-17 2014-02-28 Cytokinetics Inc Pochodne mocznika, kompozycje zawierajace pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia niewydolnosci serca
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
AU2005282492A1 (en) * 2004-09-08 2006-03-16 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007075377A2 (en) * 2005-12-15 2007-07-05 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
JP5178526B2 (ja) * 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007079003A2 (en) * 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Amide inhibitors of leukotriene a4 hydrolase
WO2010056527A2 (en) * 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8759382B2 (en) 2010-09-29 2014-06-24 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use
CN107108534B (zh) 2014-08-29 2023-05-09 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
RU2751878C2 (ru) * 2018-12-06 2021-07-19 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" 1-(Метоксибензил)-4-[2-((метоксибензил)амино)этил]пиперазины, обладающие антиаритмической активностью
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
CN114805112A (zh) * 2022-05-31 2022-07-29 常州大学 一种pde2抑制剂酰胺类衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
AU632888B2 (en) * 1989-11-22 1993-01-14 Janssen Pharmaceutica N.V. Use of piperazine acetamide derivatives against reperfusion damage
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Also Published As

Publication number Publication date
DE60126643T2 (de) 2007-10-31
ES2279790T3 (es) 2007-09-01
TWI286135B (en) 2007-09-01
NZ525259A (en) 2004-10-29
US20040029889A1 (en) 2004-02-12
KR20030044029A (ko) 2003-06-02
HK1058364A1 (en) 2004-05-14
NO325220B1 (no) 2008-02-25
ZA200302990B (en) 2004-04-22
WO2002064576A1 (en) 2002-08-22
JP2004518725A (ja) 2004-06-24
EP1339701A1 (en) 2003-09-03
NO20031797L (no) 2003-06-19
US6573264B1 (en) 2003-06-03
AU2002255466B2 (en) 2004-07-15
CA2426535A1 (en) 2002-08-22
ATE353882T1 (de) 2007-03-15
MXPA03003531A (es) 2005-01-25
CN1303074C (zh) 2007-03-07
RU2243970C1 (ru) 2005-01-10
IL155294A0 (en) 2003-11-23
US20030216409A1 (en) 2003-11-20
JP4138489B2 (ja) 2008-08-27
DE60126643D1 (de) 2007-03-29
NO20031797D0 (no) 2003-04-22
SI1339701T1 (sl) 2007-06-30
US20040192702A1 (en) 2004-09-30
CN1628107A (zh) 2005-06-15
EP1339701B1 (en) 2007-02-14
NO20031784L (no) 2003-04-23
IL155294A (en) 2009-02-11
HUP0303552A2 (hu) 2004-04-28
US6849632B2 (en) 2005-02-01
NO20031784D0 (no) 2003-04-22
HUP0303552A3 (en) 2004-06-28
PL362004A1 (en) 2004-10-18
PT1339701E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
AR034173A1 (es) Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos
AU712082B2 (en) Fibrinogen receptor antagonists
AR034244A1 (es) Derivados de 4-aminopiperidina y su uso como medicamento
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
CA2462453A1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AR035430A1 (es) Indanil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
AR037247A1 (es) Compuestos inhibidores de dipeptidil peptidasa iv (dp-iv), sus composiciones farmaceuticas y usos, y metodos de tratamiento de enfermedades de humanos tales como tolerancia alterada a la glucosa, diabetes tipo 2 e hiperglucemia
SE0104340D0 (sv) New compounds
AR032781A1 (es) Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
ES2269774T3 (es) Compuestos de piperidina como antagonistas muscarinicos.
AR018330A1 (es) Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
ATE311172T1 (de) Tüchlein und dessen verwendungen im kosmetischen bereich
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
AR029229A1 (es) Compuestos de piperazina sustituida, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento
CO5180624A1 (es) Antagonistas muscarinicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure